FindTrial
Sign In

Immunological efficacy of Jinhua Qinggan Granule for COVID-19

Immunological efficacy of Jinhua Qinggan Granule for COVID-19: an open-label, single-arm trial - COVID-19/Jinhua Qinggan Granule

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000040407
Enrollment
15
Registered
2020-05-15
Start date
2020-05-15
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Interventions

Duration: 1 hour Dose: JHQG Granule 5 g Number of doses: 1

Sponsors

Administration Department, Takanawa Clinic
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Healthy volunteers

Exclusion criteria

Exclusion criteria: Current infectious, inflammatory, or immune-related diseases

Design outcomes

Primary

MeasureTime frame
Plasma cytokine levels 1 hour after the administration of JHQG—

Secondary

MeasureTime frame
Hematology and blood biochemistry 1 hour after the administration of JHQG—

Countries

Japan

Contacts

Public ContactTomoka Ebisui

Takanawa Clinic Administration Department

jimukyoku@takanawa-clinic.com03-6433-3165

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026